Acute Hyperglycemia Induced by Hyperglycemic Clamp Affects Plasma Amyloid-β in Type 2 Diabetes
Journal of Alzheimer’s Disease · 2024
DOI: 10.3233/jad-230628 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Olov Rolandsson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Clinical Medicine, Family Medicine, Umeå University, Umeå, Sweden. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Diabetes Mellitus, Type 2, Hyperglycemia, Peptide Fragments. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Individuals with type 2 diabetes (T2D) have an increased risk of cognitive symptoms and Alzheimer’s disease (AD). Mis-metabolism with aggregation of amyloid-β peptides (Aβ) play a key role in AD pathophysiology. Therefore, human studies on Aβ metabolism and T2D are warranted.
Objective
The objective of this study was to examine whether acute hyperglycemia affects plasma Aβ 1–40 and Aβ 1–42 concentrations in individuals with T2D and matched controls.
Methods
Ten participants with T2D and 11 controls (median age, 69 years; range, 66–72 years) underwent hyperglycemic clamp and placebo clamp (saline infusion) in a randomized order, each lasting 4 hours. Aβ 1–40 , Aβ 1–42 , and insulin-degrading enzyme (IDE) plasma concentrations were measured in blood samples taken at 0 and 4 hours of each clamp. Linear mixed-effect regression models were used to evaluate the 4-hour changes in Aβ 1–40 and Aβ 1–42 concentrations, adjusting for body mass index, estimated glomerular filtration rate, and 4-hour change in insulin concentration.
Results
At baseline, Aβ 1–40 and Aβ 1–42 concentrations did not differ between the two groups. During the hyperglycemic clamp, Aβ decreased in the control group, compared to the placebo clamp (Aβ 1–40 : p = 0.034, Aβ 1–42 : p = 0.020), IDE increased ( p = 0.016) during the hyperglycemic clamp, whereas no significant changes in either Aβ or IDE was noted in the T2D group.
Conclusions
Clamp-induced hyperglycemia was associated with increased IDE levels and enhanced Aβ 40 and Aβ 42 clearance in controls, but not in individuals with T2D. We hypothesize that insulin-degrading enzyme was inhibited during hyperglycemic conditions in people with T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health and Clinical Medicine, Family Medicine, Umeå University, Umeå, Sweden.
- Department of Public Health and Clinical Medicine, Sustainable Health, Umeå University, Umeå, Sweden.
- Department of Medical and Translational Biology, Umeå University, Umeå, Sweden.
- Public Health and Clinical Medicine, Internal Medicine, Umeå University, Umeå, Sweden.
- Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Zitieren
APA
Rolandsson, O., Tornevi, A., Steneberg, P., Edlund, H., Olsson, T., Andreasson, U., Zetterberg, H., & Blennow, K. (2024). Acute Hyperglycemia Induced by Hyperglycemic Clamp Affects Plasma Amyloid-β in Type 2 Diabetes. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-230628
Vancouver
Rolandsson O, Tornevi A, Steneberg P, Edlund H, Olsson T, Andreasson U, et al. Acute Hyperglycemia Induced by Hyperglycemic Clamp Affects Plasma Amyloid-β in Type 2 Diabetes. Journal of Alzheimer’s Disease. 2024. doi:10.3233/jad-230628
BibTeX
@article{Rolandsson2024,
author = {Rolandsson, Olov and Tornevi, Andreas and Steneberg, Pär and Edlund, Helena and Olsson, Tommy and Andreasson, Ulf and Zetterberg, Henrik and Blennow, Kaj},
title = {Acute Hyperglycemia Induced by Hyperglycemic Clamp Affects Plasma Amyloid-β in Type 2 Diabetes},
journal = {Journal of Alzheimer’s Disease},
year = {2024},
doi = {10.3233/jad-230628}
}
EUVIMED